       Document 0298
 DOCN  M9630298
 TI    Prevention of SIV infection in macaques by
       (R)-9-(2-phosphonylmethoxypropyl)adenine [see comments]
 DT    9603
 AU    Tsai CC; Follis KE; Sabo A; Beck TW; Grant RF; Bischofberger N;
       Benveniste RE; Black R; University of Washington Regional Primate
       Research Center,; Seattle 98195, USA.
 SO    Science. 1995 Nov 17;270(5239):1197-9. Unique Identifier : AIDSLINE
       MED/96072971
 CM    Comment in: Science 1995 Nov 17;270(5239):1121-2
 AB    The efficacy of pre- and postexposure treatment with the antiviral
       compound (R)-9-(2-phosphonylmethoxypropyl)adenine (PMPA) was tested
       against simian immunodeficiency virus (SIV) in macaques as a model for
       human immunodeficiency virus (HIV). PMPA was administered subcutaneously
       once daily beginning either 48 hours before, 4 hours after, or 24 hours
       after virus inoculation. Treatment continued for 4 weeks and the
       virologic, immunologic, and clinical status of the macaques was
       monitored for up to 56 weeks. PMPA prevented SIV infection in all
       macaques without toxicity, whereas all control macaques became infected.
       These results suggest a potential role for PMPA prophylaxis against
       early HIV infection in cases of known exposure.
 DE    Adenine/*ANALOGS & DERIVATIVES/ADMINISTRATION & DOSAGE/  PHARMACOLOGY
       Animal  Antibodies, Viral/BLOOD  Antiviral Agents/ADMINISTRATION &
       DOSAGE/*THERAPEUTIC USE  Base Sequence  Cells, Cultured  Human  HIV
       Infections/DRUG THERAPY/*PREVENTION & CONTROL  Injections, Subcutaneous
       Leukocytes, Mononuclear/VIROLOGY  Lymph Nodes/VIROLOGY  Macaca
       fascicularis  Molecular Sequence Data  Organophosphorus
       Compounds/ADMINISTRATION & DOSAGE/*PHARMACOLOGY  Simian Acquired
       Immunodeficiency Syndrome/DRUG THERAPY/  *PREVENTION & CONTROL  Support,
       U.S. Gov't, P.H.S.  SIV/*DRUG EFFECTS/IMMUNOLOGY/ISOLATION & PURIF
       JOURNAL ARTICLE

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).

